Perceptive Advisors LLC Invests $5.94 Million in Viveve Medical, Inc. (VIVE)

Perceptive Advisors LLC purchased a new stake in Viveve Medical, Inc. (NASDAQ:VIVE) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 938,742 shares of the company’s stock, valued at approximately $5,942,000. Perceptive Advisors LLC owned approximately 0.09% of Viveve Medical as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of VIVE. Stonepine Capital Management LLC raised its position in Viveve Medical by 48.1% in the first quarter. Stonepine Capital Management LLC now owns 3,849,711 shares of the company’s stock valued at $24,256,000 after buying an additional 1,250,000 shares in the last quarter. Vanguard Group Inc. raised its position in Viveve Medical by 924.4% in the first quarter. Vanguard Group Inc. now owns 191,230 shares of the company’s stock valued at $1,210,000 after buying an additional 172,562 shares in the last quarter. Finally, Wexford Capital LP raised its position in Viveve Medical by 23.9% in the first quarter. Wexford Capital LP now owns 777,124 shares of the company’s stock valued at $4,919,000 after buying an additional 150,000 shares in the last quarter. Institutional investors and hedge funds own 61.19% of the company’s stock.

Institutional Ownership by Quarter for Viveve Medical (NASDAQ:VIVE)

Viveve Medical, Inc. (NASDAQ VIVE) traded up 3.95% on Friday, reaching $7.90. The company’s stock had a trading volume of 192,523 shares. The stock’s 50 day moving average price is $7.66 and its 200 day moving average price is $5.96. The company’s market cap is $152.90 million. Viveve Medical, Inc. has a 12 month low of $3.75 and a 12 month high of $11.16.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Thursday, May 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.06. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $2.70 million. Viveve Medical had a negative return on equity of 232.94% and a negative net margin of 255.11%. Equities research analysts forecast that Viveve Medical, Inc. will post ($1.81) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Perceptive Advisors LLC Invests $5.94 Million in Viveve Medical, Inc. (VIVE)” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.wkrb13.com/markets/2228714/perceptive-advisors-llc-invests-5-94-million-in-viveve-medical-inc-vive.html.

VIVE has been the topic of several recent research reports. Cowen and Company initiated coverage on Viveve Medical in a research report on Wednesday, May 3rd. They issued an “outperform” rating and a $11.00 price target on the stock. Raymond James Financial, Inc. initiated coverage on Viveve Medical in a research report on Thursday, May 25th. They issued an “outperform” rating and a $10.00 price target on the stock. ValuEngine upgraded Viveve Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, B. Riley restated a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a research report on Wednesday, February 22nd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Viveve Medical presently has an average rating of “Buy” and an average target price of $12.80.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Want to see what other hedge funds are holding VIVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viveve Medical, Inc. (NASDAQ:VIVE).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228714/perceptive-advisors-llc-invests-5-94-million-in-viveve-medical-inc-vive.html

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.